New hope for boosting blood levels in sickle cell patients
NCT ID NCT07282210
Summary
This study is testing if adding a new drug called SIL-8301 (senicapoc) to standard sickle cell treatment can improve anemia and reduce disease complications. It will involve about 105 young adults (16-35) with a specific type of sickle cell disease who have low blood counts despite current medication. Participants will take either the study drug or a placebo daily for up to 24 weeks while continuing their usual care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.